Spero Therapeutics (SPRO) Other financing activities (2018 - 2022)

Spero Therapeutics (SPRO) has reported Other financing activities for 5 consecutive years, with $1000.0 the latest figure, recorded in Q4 2022.

• For the quarter ending Q4 2022, Other financing activities fell 100.0% year-over-year to $1000.0; the trailing twelve-month figure through Sep 2023 stood at $1000.0 (down 100.0% YoY), and the FY2022 full-year result was $420000.0, down 99.16% from the prior year.
• Other financing activities fell to $1000.0 in Q4 2022 per SPRO's latest filing, from $231000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $48.5 million in Q4 2021 and bottomed at $1000.0 in Q4 2022.
• Historically, Other financing activities has averaged $3.1 million across 5 years, with a median of $201000.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Other financing activities jumped 4012.88% in 2021, then sank 100.0% in 2022.
• Over 5 years, Other financing activities stood at $138000.0 in 2018, then dropped by 28.99% to $98000.0 in 2019, then soared by 1104.08% to $1.2 million in 2020, then surged by 4012.88% to $48.5 million in 2021, then tumbled by 100.0% to $1000.0 in 2022.
• According to Business Quant data, Other financing activities over the past three periods registered $1000.0, $231000.0, and $188000.0 for Q4 2022, Q2 2022, and Q1 2022 respectively.